Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
TRICYCLIC COMPOUND USED AS GPR84 ANTAGONIST
Document Type and Number:
WIPO Patent Application WO/2022/268088
Kind Code:
A1
Abstract:
The present invention relates to a tricyclic compound used as a GPR84 antagonist, and in particular relates to a tricyclic compound having a structure shown in formula I, and tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts or prodrugs thereof; the definitions of the ring Cy, L1, R1 are as described in the present invention; the tricyclic compound has significant GPR84 antagonism, good pharmaceutical developability and high safety.

Inventors:
ZHANG XUEJUN (CN)
ZANG YANG (CN)
WEI WENJUN (CN)
LI QUN (CN)
ZHAO XIN (CN)
XU QING (CN)
NI PING (CN)
LI LI'E (CN)
YANG JUN (CN)
Application Number:
PCT/CN2022/100224
Publication Date:
December 29, 2022
Filing Date:
June 21, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY (CN)
International Classes:
C07D471/04; A61K31/4375; A61P29/00; C07D519/00
Domestic Patent References:
WO2015197550A12015-12-30
WO2013092791A12013-06-27
Foreign References:
CN104870445A2015-08-26
CN111343986A2020-06-26
CN103998448A2014-08-20
CN202110685568A2021-06-21
Other References:
LABÉGUÈRE FRÉDÉRIC, DUPONT SONIA, ALVEY LUKE, SOULAS FLORILÈNE, NEWSOME GREGORY, TIRERA AMYNATA, QUENEHEN VANESSA, MAI THI THU TRA: "Discovery of 9-Cyclopropylethynyl-2-(( S )-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1- a ]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, no. 22, 25 November 2020 (2020-11-25), US , pages 13526 - 13545, XP055914991, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.0c00272
MAEHR, J. CHEM. ED., vol. 62, 1985, pages 114 - 120
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: